MISC

2016年

Cytomegalovirus Pneumonia after Anti-CC-chemokine Receptor 4 Monoclonal Antibody (Mogamulizumab) Therapy in an Angioimmunoblastic T-cell Lymphoma Patient

INTERNAL MEDICINE
  • Yoshimi Ishii
  • ,
  • Megumi Itabashi
  • ,
  • Ayumi Numata
  • ,
  • Wataru Yamamoto
  • ,
  • Kenji Motohashi
  • ,
  • Maki Hagihara
  • ,
  • Kenji Matsumoto
  • ,
  • Shin Fujisawa

55
6
開始ページ
673
終了ページ
675
記述言語
英語
掲載種別
DOI
10.2169/internalmedicine.55.5644
出版者・発行元
JAPAN SOC INTERNAL MEDICINE

Angioimmunoblastic T-cell lymphoma (AITL) is an aggressive T-cell lymphoma. A 63-year-old man was diagnosed with AITL. He received 6 cycles of CHOP therapy, but showed progressive disease. Subsequently, he received ESHAP chemotherapy; however, it was not effective. He received mogamulizumab (an anti-CCR4 monoclonal antibody). After 4 cycles, his respiratory condition worsened and he was diagnosed with cytomegalovirus (CMV) pneumonia. Despite antiviral and antibiotic therapy, he died. We speculate that the combination of progressive lymphoma with mogamulizumab and chemotherapy likely caused CMV pneumonia. Because mogamulizumab therapy causes immunosuppression, if CMV pneumonia is suspected, then rapid treatment should be initiated.

Web of Science ® 被引用回数 : 4

リンク情報
DOI
https://doi.org/10.2169/internalmedicine.55.5644
Web of Science
https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=JSTA_CEL&SrcApp=J_Gate_JST&DestLinkType=FullRecord&KeyUT=WOS:000373202100022&DestApp=WOS_CPL